Identification of a hypoxia-regulated miRNA signature in bladder cancer and a role for miR-145 in hypoxia-dependent apoptosis by Blick, C. et al.
Identification of a hypoxia-regulated miRNA
signature in bladder cancer and a role for
miR-145 in hypoxia-dependent apoptosis
C Blick1,2, A Ramachandran1,3, R McCormick1, S Wigfield1, D Cranston2, J Catto4 and A L Harris*,1
1Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital,
Oxford OX3 9DS, UK; 2Department of Urology, Churchill Hospital, Oxford OX3 7LE, UK; 3Cancer Research UK London Research
Institute, Lincoln’s Inn Fields Laboratories, London WC2A 3LY, UK and 4The Academic Department of Urology and Institute for
Cancer Studies, University of Sheffield, Sheffield S10 2RX, UK
Background: Hypoxia leads to the stabilisation of the hypoxia-inducible factor (HIF) transcription factor that drives the expression
of target genes including microRNAs (miRNAs). MicroRNAs are known to regulate many genes involved in tumourigenesis. The
aim of this study was to identify hypoxia-regulated miRNAs (HRMs) in bladder cancer and investigate their functional significance.
Methods: Bladder cancer cell lines were exposed to normoxic and hypoxic conditions and interrogated for the expression of 384
miRNAs by qPCR. Functional studies were carried out using siRNA-mediated gene knockdown and chromatin immunoprecipita-
tions. Apoptosis was quantified by annexin V staining and flow cytometry.
Results: The HRM signature for NMI bladder cancer lines includes miR-210, miR-193b, miR-145, miR-125-3p, miR-708 and miR-
517a. The most hypoxia-upregulated miRNA was miR-145. The miR-145 was a direct target of HIF-1a and two hypoxia response
elements were identified within the promoter region of the gene. Finally, the hypoxic upregulation of miR-145 contributed to
increased apoptosis in RT4 cells.
Conclusions: We have demonstrated the hypoxic regulation of a number of miRNAs in bladder cancer. We have shown that miR-
145 is a novel, robust and direct HIF target gene that in turn leads to increased cell death in NMI bladder cancer cell lines.
Bladder cancer is the most common tumour of the urinary system
(Office for National Statistics, 2010). Initial tumour resection and
adjuvant therapy are associated with a high 5-year survival rate for
bladder cancer (75%). However, the frequency of tumour
recurrence can be as high as 80%, with disease progression
occurring in up to 45% of patients (van Rhijn et al, 2009).
Treatment and the necessity for regular surveillance contribute to
the economic burden of this disease, with bladder cancer having
the highest lifetime cost per patient of all cancers (Lee et al, 2012).
In Europe and North America,B90% of cases of bladder cancer
are derived from the epithelial layer of the bladder and are termed
transitional cell carcinomas (TCCs) (Luis et al, 2007). The majority
(70–80%) of TCCs are confined to the bladder mucosa or lamina
propria and are referred to as non-muscle-invasive cancers
(NMIs). Muscle-invasive (MI) bladder cancer is defined by
tumours that invade the muscularis propria and spread to the
perivesical tissue and surrounding organs. The MI and NMI forms
of bladder cancer have distinct underlying aetiologies, with NMI
cancer characterised by increased expression and activating
mutations of FGFR3, the PI3 kinase pathway and RAS (Castillo-
Martin et al, 2010; Goebell and Knowles, 2010), and MI bladder
cancer associated with mutations in TP53, RB and PTEN (Aveyard
et al, 1999; Bakkar et al, 2003; van Rhijn et al, 2004).
Apart from somatic mutations intrinsic to cancer cells,
additional factors play an important role in tumour growth
including the extrinsic tumour microenvironment. A key feature of
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this microenvironment is hypoxia, a state of low oxygen tension.
Hypoxia is an important component of tumourigenesis and a
feature of most solid cancers. The cellular responses to hypoxia are
mediated by the transcription factor hypoxia-inducible factor
(HIF), an obligate dimer of a (HIF-1a) and b (HIF-1b) subunits.
The active HIF complex binds to hypoxia response elements
(HREs) of target genes leading to their transcriptional upregula-
tion. Hypoxia-induced genes regulate many biological processes
such as CA9 involved in pH regulation, VEGF involved in
angiogenesis and LDHA involved in metabolism.
Regions of hypoxia have been demonstrated in both NMI and
MI bladder tumours, with colocalisation of the hypoxic markers
CA9 and VEGF seen on the luminal surface of NMI tumours and
around the periphery of necrotic areas and in hypoxic cores in
larger invasive tumours (Turner et al, 2002; Theodoropoulos et al,
2004). Levels of HIF-1a expression correlate with VEGF expres-
sion, microvessel density and ki67 proliferation index, supporting
the role of the hypoxic response in various tumourigenic processes
described in NMI and MI bladder cancer such as angiogenesis and
proliferation (Jones et al, 2001; Chai et al, 2008).
An important class of regulators of gene expression are
microRNAs (miRNAs). MicroRNAs are small (18–22 nucleotides),
noncoding, single-stranded RNA that post-transcriptionally reg-
ulate gene expression. The loss of components of the miRNA
processing machinery, including the double-stranded RNA-bind-
ing protein DGCR8 (Hsu et al, 2012) and the RNase DICER
(Bernstein et al, 2003), results in embryonic lethality in mice as
well as defects in neuronal development, demonstrating the
importance of the RNAi pathway in development and tissue
homeostasis (Bauersachs and Thum, 2011). In addition, changes in
miRNA expression occur in the majority of human tumours
(Volinia et al, 2006) and miRNAs have been implicated in all the
hallmarks of cancer (Lee et al, 2007; Cole et al, 2008; Xiao et al,
2008).
Hypoxia-regulated miRNAs (HRMs) have been identified in
many cancer types. The miR-210 is currently acknowledged as the
most robust HRM and is consistently upregulated as a result of
HIF activation across a number of different tumour types including
renal and head and neck cancers (Gee et al, 2010; Neal et al, 2010).
Additional HRMs include miR-155 (Hua et al, 2006; Babar et al,
2011; Bruning et al, 2011) and miR-424 (Ghosh et al, 2010),
although these appear to be regulated in a cell line-dependent
manner.
The characterisation of miRNAs differentially regulated in
bladder cancer has been the focus of recent studies aimed at
establishing a role for miRNAs as diagnostic and prognostic
markers. The miR-23b and miR-221 were found to be differentially
regulated between the normal bladder urothelium and bladder
tumours (Gottardo et al, 2007). Furthermore, the ratio between
miR-21 and miR-205 may differentiate between invasive and
noninvasive bladder cancer (Neely et al, 2010).
We have previously shown that miR-100 expression is decreased
in bladder cancer compared with the normal urothelium (Catto
et al, 2009). In addition, we have found that miR-100 levels are
suppressed by hypoxia and that both hypoxia and miR-100 are
responsible for regulating FGFR3 levels in NMI bladder cancer cell
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Figure 1. Hypoxia-regulated miRNAs (HRMs) in bladder cancer. (A) Venn diagram representation of the 30 most induced miRNAs in RT4 and
RT112 cells. (B) Median fold change from three independent experiments of the 10 most induced miRNAs in RT4 and RT112 cells.
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lines (Blick et al, 2013). However, to date, no comprehensive
analysis has been performed to identify HRMs in bladder cancer.
The initial aim of this study was to identify HRM signatures in
NMI and MI bladder cancer. Furthermore, we go on to
demonstrate that one of the miRNA in the signature, miR-145, is
a bona fide HIF target in NMI bladder cancer and show that it
plays a role in controlling cell viability after sustained exposure to
hypoxia.
MATERIALS AND METHODS
Cell culture. The cell lines RT4, RT112, T24 and HT1376 were
obtained from Cancer Research UK Cell Services (Clare Hall
Laboratories, London, UK) and cultured as previously described
(Blick et al, 2013). A hypoxia incubator (MiniGalaxy A, RS
Biotech, Irvine, Scotland) or hypoxia workstation (In Vivo2,
Ruskinn Technology, Bridgend, UK) were used to achieve low
oxygen conditions (1% or 0.1% O2 respectively) in parallel to cells
maintained in normoxic conditions (5% CO2, 37 1C, 21% O2) for
the indicated time. All experiments were done in triplicate from
independent cell cultures.
RNA extraction, reverse transcription and quantitative PCR
(qPCR) for microRNAs. Cells were lysed with Tri Reagent
(Sigma-Aldrich, St Louis, MO, USA), and RNA extracted using
chloroform followed by ethanol precipitation. RNA (350 ng) was
reverse transcribed using the TaqMan Megaplex Primer Pool A
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Figure 2. Validation of common HRMs in bladder cancer cell lines. Expression of (A–D) miR-210 and (E–H) miR-193b in (A and E) RT4,
(B and F) T24, (C and G) RT112 and (D and H) HT1376 cells exposed to normoxia (N; white bars), 1% O2 (hatched bars) or 0.1% O2 (black bars)
for the indicated time. Data are mean and s.e.m. of three independent experiments. *Po0.05, **Po0.01, ***Po0.001.
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mix and the TaqMan Reverse Transcription Kit (Applied
Biosystems, Warrington, UK). The miRNA expression was assayed
on either the TaqMan Array Human MicroRNA A Card or using
individual assays (Applied Biosystems). Real-time PCR runs were
done on the 7900HT Fast Real Time PCR System (Applied
Biosystems). For each miRNA, each sample was assayed in
triplicate. The miRNA expression was normalised using either
RNU44 or RNU48 using the comparative Ct method (Livak and
Schmittgen, 2001) and presented as fold change relative to
expression in normoxia.
The siRNA, miRNA mimics and anti-miRs. The siRNAs against
HIF-1a and HIF-2a have been previously described (Blick et al,
2013). The scramble (Scr) and siRNA sequence against p53 were
synthesised by Eurogentec (Liege, Belgium) and are as follows:
Scr: 50-ACGACACGCAGGUCGUCAU-30 and sip53: 50-GACUC
CAGUGGUAAUCUAC-30. The miR-145 mimic (mimic-miR-145)
and anti-miR (anti-miR-145) and appropriate controls were
purchased from Dharmacon (Lafayette, CO, USA).
Transfection protocol. Cells were reverse transfected with siRNA,
mimic-miR-145 or anti-miR-145 with Oligofectamine (Invitrogen,
Paisley, UK) according to the manufacturer’s instructions as
previously described (Blick et al, 2013).
Chromatin immunoprecipitation. Chromatin immunoprecipita-
tions (ChIPs) were performed using the EZ-ChIP kit (Millipore,
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Figure 3. Validation of HRMs in RT4 cells. Expression of (A) miR-518-3p, (B) miR-125a-3p, (C) miR-519d, (D) miR-708, (E) miR-525-3p, (F) miR-517,
(G) miR-519a and (H) miR-335 in RT4 cells exposed to normoxia (N; white bars), 1% O2 (hatched bars) or 0.1% O2 (black bars) for 24 h. Data are
mean and s.e.m. of three independent experiments. *Po0.05, **Po0.01, ***Po0.001.
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Watford, UK) according to the manufacturer’s instructions. Briefly,
RT4 cells were either incubated in normoxia or 0.1% O2 for 24 h.
Proteins were first crosslinked to DNA with 1% formaldehyde for
10min at room temperature and excess formaldehyde was
quenched with 125mM glycine for 5min. Cells were harvested by
scraping and resuspended in SDS lysis buffer with protease
inhibitors to get a cell suspension at 2 107 cells per ml. Genomic
DNA was sheared using a Diagenode Bioruptor (Lie`ge, Belgium)
sonicator to get fragments sizes in the range of 250–750 bp.
Sheared DNA was precleared with protein G beads and
immunoprecipitations were performed with anti-HIF-1a and
anti-RNA polymerase II antibodies using 100 ml of sheared DNA
per antibody. After overnight incubation at 4 1C, antibodies with
bound chromatin were purified with protein G beads, the protein/
DNA complexes eluted and then the crosslinks reversed to release
the sheared genomic DNA.
Primers. Primers were purchased from Invitrogen. The following
primer pairs were used for the ChIP PCRs: miR-145 HRE1_F:
50-GTGAATGAGGCCGTGAACAGAGAC-30 and miR-145 HRE1_R:
50-CATGTCCACGGTTCTAGTTTCTTG-30; miR-145_HRE2_F: 50-AG
CACCGGGGGCAGGTCAAG-30 and miR-145_HRE2_R: 50-GGCA
TTTTTAAGCAGCTGGCACTG-30; CA9_HRE_F: 50-GTCCATGGC
CCCGATAACCTTCTG-30 and CA9_HRE_R: 50-GGGGCAAC
CTCTGGGGATGGAC-30; UBC_F: 50-TTGCTGGCAAATATCA
GACG-30 and UBC_R: 50-GCAAGACCATCACCCTTGAG-30.
Flow cytometry. RT4 cells were reverse transfected with mimic-
145 or anti-miR-145 and appropriate controls and either kept in
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Figure 4. Validation of HRMs in T24 cells. Expression of (A) miR-518f, (B) miR-200a, (C) miR-99a, (D) miR-107, (E) miR-194, (F) miR-212,
(G) miR-15a and (H) miR-150 in T24 cells exposed to normoxia (N; white bars), 1% O2 (hatched bars) or 0.1% O2 (black bars) for 24 h.
Data are mean and s.e.m. of three independent experiments. *Po0.05, **Po0.01, ***Po0.001.
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normoxia or placed in 0.1% O2. On days 3, 4 and 5, cells were
harvested with trypsin and pelleted. Cells were stained with
annexin-V-AlexaFluor 647 (Invitrogen; 5 ml) and propidium iodide
(Invitrogen; 50 mgml 1) in 100 ml of annexin V binding buffer
(BD Pharmagen, San Jose, CA, USA) for 15min at room
temperature. Subsequently, 400 ml of annexin V staining buffer
was added to each sample, cells were placed on ice and analysed by
flow cytometry using a Cyan ADP Flow Cytometer (Beckman
Coulter, Indianapolis, IN, USA). Data collection and analysis was
performed using Summit version 1 (DAKO, Glostrop, Denmark).
Correlation of miRNA expression. We have previously char-
acterised the expression of miR-210, miR-193b and miR-145 in 55
primary bladder cancer samples (both NMI and MI) and normal
urothelium (n¼ 20) by qPCR (Catto et al, 2009). The correlation
of normalised expression of miR-145, miR-210 and miR-193b was
investigated by linear regression.
RESULTS
Hypoxia regulates both common and distinct miRNAs in MI
and NMI bladder cancer. To generate HRM signatures in bladder
cancer, the expression of 384 miRNAs in the TaqMan miRNA pool
A were analysed in the noninvasive cell line RT4 and the invasive
cell line T24 after exposure to normoxia or 0.1% hypoxia for 24 h.
A number of criteria were used to refine the list of HRMs. First,
miRNAs with CT values440 in both normoxia and hypoxia were
excluded as their expression levels were likely to be too low to
accurately quantify. Second, attention was focussed on the 30 most
up- or downregulated miRNAs for each cell line as these were
likely to be true hits (Supplementary Figure 1). In agreement with
other cell lines, miR-210 was robustly induced by hypoxia in both
cell lines (Supplementary Figure 1). Seven of the 30 most hypoxia-
upregulated miRNAs were common to both cell lines (Figure 1A).
However, a number of the differentially regulated miRNAs were
unique to each cell line (Figure 1A).
In RT4, miR-145 was the most robust HRM, being induced
more strongly than miR-210 (Supplementary Figure 1 and
Figure 1B). Furthermore, a number of miRNAs belonging to the
C19MC cluster on chromosome 19 (Bortolin-Cavaille et al, 2009;
Ren et al, 2009) including miR-518a-3p, 515-5p and 525-3p were
also upregulated in response to hypoxia in this line. In T24, three
members of the miR-200 family, including miR-200a, 200b and
200c, were upregulated in response to hypoxia (Supplementary
Figure 1). Additional miRNAs upregulated in response to hypoxia
in T24 cells included miR-150 and miR-15a. Across both cell lines,
only 3 miRNAs were upregulated 410-fold in hypoxia: miR-145
and miR-210 in RT4 and miR-518f in T24 (Figure 1B).
Validation of low-density arrays reveals novel HRMs in bladder
cancer cell lines. To validate the findings of the arrays, the
expression of the following miRNAs was examined with individual
assays – miRs 145, 518-3p, 125a-3p, 519d, 708, 525-3p, 517a, 519a,
and miR-335 in RT4 and miRs 518f, 150, 200a, 15a, 99a, 107, 194
and 212 in T24. Validated targets in RT4 were also examined in a
second NMI line, RT112, whereas confirmed targets in T24
were investigated in another MI line HT1376. The expression of
miR-210 and miR-193b were examined in all cell lines.
The robust HRM miR-210 was induced after exposure to low
oxygen in all bladder cancer cell lines (Figure 2A–D). In addition,
miR-193b was also induced by hypoxia in all cell lines except
HT1376 (Figure 2E–H). We also examined the expression of these
two miRNAs in h-TERT, an immortalised normal urothelial cell
line. Both miR-210 and miR-193b were upregulated by hypoxia in
h-TERT cells, although the fold induction was lower than those
observed in the bladder cancer cell lines (Supplementary Figure 2).
In addition to miR-145 (Figure 5), significant hypoxic
upregulation of miR-518-3p, 125a-3p, 708, 517a, 519a and
miR-335 was confirmed in RT4 cells (Figure 3A–F). MiR-525-3p
and miR-519d were not significantly induced in response to
hypoxia in RT4 cells (Figure 3G and H). In a second NMI bladder
cancer line RT112, hypoxic induction of miR-145, 125-3p, miR-
708 and miR-517a was observed (Supplementary Figure 3). The
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expression of miR-519a and miR-335 was unchanged by hypoxia
(Supplementary Figure 3), whereas miR-518-3p was undetectable
in these cells.
Using individual assays, the hypoxic induction of miR-518f,
200a, 15a, 99a, 107, 194 and 212, but not miR-150, was confirmed
in T24 (Figure 4). In a second MI cell line, HT1376, miR-15a, 99a
and 107 were unchanged by exposure to hypoxia, miR-194 and 212
were suppressed (Supplementary Figure 4) and miR-518f and miR-
200a were undetectable.
Hypoxic upregulation of miR-145 requires HIF-1a but not
p53. As mentioned previously, robust induction of miR-145
was observed in RT4 (Figures 1 and 5A ). MiR-145 was also
induced upon treatment of cells with the hypoxia mimetic
DMOG in normoxia (Figure 5B). The upregulation of miR-145
in RT4 was of particular interest as miR-145 can, in part, be
regulated by p53 (Sachdeva et al, 2009). As RT4 cells have wild-
type p53, we investigated whether p53 was required for the
hypoxic induction of miR-145. Knockdown of p53 did not reduce
miR-145 expression in hypoxia (Figure 5C). However, knock-
down of p53 attenuated the hypoxic induction of miR-210
(Figure 5D).
MiR-145 is a direct HIF-1a target gene. As the expression of
miR-145 was induced by hypoxia and DMOG, we hypothesised
that it was a direct HIF target gene in RT4 cells. Indeed,
knockdown of HIF-1a but not HIF-2a attenuated the hypoxic
induction of miR-145 (Figure 6A). A similar pattern of expression
was observed for miR-210 (Figure 6B), a well-characterised HIF-1a
target miRNA.
Using MatInspector (Cartharius et al, 2005), two putative HREs
were identified in the promoter region of miR-145 (Figure 6C). To
confirm that they were true HIF binding sites, ChIPs were
performed with HIF-1a and RNA polymerase II antibodies. The
HRE1, which is closer to the transcription start site (TSS)
(Figure 6C), was enriched with both HIF-1a and RNA polymerase
II antibodies (Figure 6D). The HRE2 that is 1.1 kb upstream of the
TSS was only enriched with the HIF-1a antibody (Figure 6D). As a
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positive control, the HRE of the robust HIF-1a target gene CA9
was enriched with both the HIF-1a and RNA polymerase II
antibodies (Figure 6D) and the negative control UBC was not
enriched in normoxia or hypoxia with either antibody (Figure 6D).
Therefore, the hypoxic induction of miR-145 appears to be a direct
effect of HIF-1a dependent transactivation.
MiR-145 regulates apoptosis under hypoxia in RT4 cells. As
overexpression of miR-145 has been shown to affect cell viability in
bladder cancer lines (Chiyomaru et al, 2010), we investigated
whether miR-145 may play a role in cell viability in hypoxia in RT4
cells. Transfection of mimic-miR-145 in normoxia led to an
increase in apoptotic annexin Vþ /PI cells and necrotic annexin
Vþ /PIþ cells compared with mimic-ctrl transfected cells and a
concomitant decrease in viable annexin V /PI cells (Figure 7A
and B and Table 1).
Exposure of anti-miR-ctrl transfected cells to hypoxia led to a
decrease in cell viability as seen by an increase in necrotic annexin
Vþ /PIþ cells and a decrease in viable annexin V /PI cells
(Figure 7C and D and Table 1). Importantly, transfection of anti-
miR-145 improved cell viability in hypoxia, with a decrease in
annexin Vþ /PIþ cells and an increase in annexin V /PI cells
(Figure 7E and Table 1). Thus, the hypoxic upregulation of miR-
145 contributes to cell death under hypoxia in RT4 cells.
MiR-145 expression correlates with that of miR-210 and miR-
145 in primary bladder cancer specimen. To determine the
biological relevance of HRMs in vivo, we examined the correlation
of miR-145, miR-210 and miR-193b expression in primary bladder
cancer samples and in the normal bladder urothelium. The
expression of miR-193b was strongly correlated to that of miR-145
(Figure 8A) and miR-210 (Figure 8B); the expression of miR-145
did not correlate to the expression of miR-210 in vivo (Figure 8C).
DISCUSSION
Variations in gene expression among different tumour types led us
to hypothesise that exposure to hypoxia may lead to changes in
miRNA expression that are unique to bladder cancer. Of the 25
miRNAs most highly induced in RT4 and T24, two cell lines that
represent NMI and MI bladder cancer types respectively, the
majority were exclusive to one or other. This is likely because of the
differences between the molecular pathways involved in the two
forms of bladder cancer that these two cell lines represent. Seven
miRNAs were induced by hypoxia in both cell lines. They include
the universal HRM miR-210 (Kulshreshtha et al, 2007; Camps
et al, 2008) and miR-193b that is induced by hypoxia in the colon
cancer line CaCo2 (Bruning et al, 2011). Thus, these may represent
cell type-independent targets of HIF but further validation,
particularly of miR-193b, is required. The fold induction of miR-
210 in hypoxia was lower in the immortalised urothelium line
h-TERT compared with the cancer-derived cell lines. This could
reflect differences between cell lines or may suggest that the
hypoxic response in cancer cells is augmented by additional
pathways such as mTOR (Hudson et al, 2002).
Of note was the hypoxic induction of co-regulated miRNAs.
Both miRNAs derived from pre-miR-125a, miR-125a-3p and miR-
125a-5p (Jiang et al, 2010) were induced by hypoxia in RT4 and
T24 cells. Furthermore, almost half of the 25 most hypoxia-
induced miRNAs in RT4 cells, including miR-518a-3p, 515-5p and
525-3p, are from the primate-specific C19MC cluster on chromo-
some 19 (Bortolin-Cavaille et al, 2009). The induction of more
than one miRNA from a precursor/cluster strengthens the notion
that these are bona fide HRMs.
The hypoxic induction of miR-145, miR-125-3p, miR-708 and
miR-517a was common to both NMI bladder cancer cell lines
(RT4 and RT112). These four miRNAs, along with miR-210 and
miR-193b, may form part of a HRM signature for NMI bladder
cancer. Indeed, significant correlation was observed between
miR-193b expression and that of miR-145 and miR-210 in
NMI bladder cancer samples in vivo. In contrast, the majority
of hypoxia-induced miRNAs in T24 cells could not be
ratified in a second invasive bladder cancer line HT1376. Thus,
MI bladder cancer-derived cell lines respond to hypoxia in a
more varied manner, suggesting they are more divergent from
each other.
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Members of the miR-200 family, associated with EMT, have
been found to be downregulated in advanced bladder cancer
(Wiklund et al, 2011).
In RT4 cells, the hypoxic induction of miR-145 was dependent
on HIF-1a with two HREs identified in the promoter region.
MiR-145, thus, represents a new HIF-1a target gene in NMI
bladder cancer lines and a novel HRM. The expression of miR-145
is known to be regulated by p53 (Sachdeva et al, 2009). However,
in RT4 cells that have wild-type p53, knockdown of p53 did not
affect the hypoxic induction of miR-145. In ovarian cancer, the
presence of a nonfunctioning p53 has been shown to be critical for
miR-145 to fail in its role as a tumour suppressor (Dong et al, 2014).
In contrast, knockdown of p53 attenuated the hypoxic induction of
miR-210. The HIF-1a has previously been shown to stabilise and
activate wild-type p53 (An et al, 1998) and, as seen in our hands, loss
of p53 attenuated the hypoxic induction of miR-210 in mouse
embryonic fibroblasts (Mutharasan et al, 2011). The synergy and
crosstalk between HIF and p53 warrants further investigation.
The miRNA cluster 143-145 has been found to be down-
regulated in many cancer types and is considered a tumour
suppressor in ovarian, breast and pancreatic cancers (Dong et al,
2014; Khan et al, 2014; Yan et al, 2014). The locus is suppressed by
RAS signalling (Kent et al, 2010; Sachdeva and Mo, 2010). In
bladder cancer, immunohistochemistry of miR-145 showed
homogenous but reduced staining compared with normal tissue
in papillary tumours, heterogenous expression in MI tumours and
no staining in carcinoma in situ (Ostenfeld et al, 2010). The miR-
145 is downregulated in invasive bladder tumours and described as
a tumour suppressor (Yoshino et al, 2013). It has also been shown
to inhibit invasion in bladder cancer by targeting PAK1 (Kou et al,
2014) and inhibit bladder cancer initiation by targeting IGFR1(Zhu
et al, 2014). Additional validated targets of miR-145 include
C-MYC (Sachdeva et al, 2009), OCT4, SOX2 and KLF4 (Xu et al,
2009), thereby suppressing tumour growth and stem cell renewal.
Conversely, overexpression of miR-145 suppresses growth and
invasion in breast cancer cell lines (Kent et al, 2010; Sachdeva and
Mo, 2010). Furthermore, miR-145 has been shown to lead to
caspase-dependent and -independent cell death in bladder cancer
cell lines (Chiyomaru et al, 2010; Ostenfeld et al, 2010; Noguchi
et al, 2013). The miR-145 has also been shown to regulate PAI-1,
an oncogene associated with a poor prognosis in bladder cancer,
suggesting miR-145 may have a role as a prognostic indicator. In
agreement with this, in this study, we have shown that increased
levels of miR-145 in hypoxia contribute to cell death of RT4 cells. It
is possible that one of the adaptive mechanisms in more malignant
cancer types is the loss of hypoxic induction of miR-145, thus
providing a survival advantage to cells.
In conclusion, we have shown that a relatively small-scale
analysis can deliver novel insights into hypoxia biology. We have
identified a number of miRNAs that could form part of a HRM
signature, particularly in NMI bladder cancer. This strategy is
capable of identifying direct HIF target genes, as demonstrated by
miR-145. Finally, hypoxia-induced miRNAs are functionally
relevant, as we have shown that miR-145 controls apoptosis in
NMI bladder cancer cell lines. It may be worthwhile to validate the
HRM signature identified herein in a larger cohort of NMI bladder
cancer samples.
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Table 1. Percentage of cells in each quarter
Mimic-ctrl N Mimic-145 N
R3 (apoptotic) 5.1 9.3
R4 (necrotic) 10.8 14.2
R5 (viable) 74.5 67.5
R6 (other) 9.5 9.0
Anti-miR-ctrl N Anti-miR-ctrl H Anti-miR-145 H
R3 (apoptotic) 3.6 2.4 3.5
R4 (necrotic) 15.2 35.1 23.4
R5 (viable) 78.9 58.3 68.6
R6 (other) 2.2 4.2 4.4
Abbreviations: ctrl¼ control; H¼ hypoxia; miR¼microRNA; N¼normoxia.
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